NewsBenzingaViking Therapeutics beginnt mit einer explorativen Studie zur oralen Erhaltungsdosierung von VK2735, seinem Dualagonisten der Rezeptoren für das Glucagon-ähnliche Peptid 1 und das glukoseabhängige insulinotrope Polypeptid Viking Therapeutics beginnt mit einer explorativen Studie zur oralen Erhaltungsdosierung von VK2735, seinem Dualagonisten der Rezeptoren für das Glucagon-ähnliche Peptid 1 und das glukoseabhängige insulinotrope Polypeptid Benzinga 2026.10.06 11:09 (GMT+0) Open on Benzinga Other news Vitalik: Ethereum should move heavy cryptographic computation to clients, with on-chain only verifying proofs and results 'This Is What I Will Be Doing’: Elon Musk Says He’ll Give Shares To The Public After Anthropic Announces 5% Fund BlackRock: Tokenized Funds Are Accelerating Their Integration into Wall Street's Underlying Financial Plumbing SentinelOne: Clear Market Share Gains As AI Paranoia Drives Deals (NYSE:S) The Winners Inside SCHD - October 2026 Trader liquidates PONS and AI tokens, losing $645,000 in 10 hours
Vitalik: Ethereum should move heavy cryptographic computation to clients, with on-chain only verifying proofs and results
'This Is What I Will Be Doing’: Elon Musk Says He’ll Give Shares To The Public After Anthropic Announces 5% Fund
BlackRock: Tokenized Funds Are Accelerating Their Integration into Wall Street's Underlying Financial Plumbing
